Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Literature
1.
Oaknin A, Rodríguez-Freixinós V, Díaz de Corcuera I et al (2012) SEOM guidelines for endometrial cáncer. Clin Transl Oncol 14:512–515PubMedCrossRef
2.
Johnson N, Bryant A, Miles T et al (2011) Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev (10):CD003175
3.
Hogberg T, Signorelli M, de Oliveira CF et al (2010) A randomized phase III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) (abstract). Eur J Cancer 46(13):2422–2431PubMedCrossRef
4.
Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecolgic Oncology Group study. J Clin Oncol 24:36–44PubMedCrossRef
Metadata
Title
Comments on “SEOM guidelines for endometrial cancer”
Author
R. Vergés
Publication date
01-12-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0957-1

Other articles of this Issue 12/2012

Clinical and Translational Oncology 12/2012 Go to the issue

Educational Series – Red Series*

Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy

Research Article

Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer

Research Article

Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model

Educational Series – Blue Series

Therapeutic nanosystems for oncology nanomedicine

Research Article

Characteristics and long-term survival of colorectal cancer patients aged 44 years and younger

Editorial

Depicting the evolving scenario of translational-guided drug development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits